Anthropic announced a board appointment yesterday that might surprise at first glance: Vas Narasimhan, CEO of Novartis and one of the most influential pharma executives in the world, now sits on the Board of Directors.
Who Is Narasimhan?
Vas Narasimhan was a physician and scientist before becoming a manager. He worked on HIV/AIDS, malaria, and tuberculosis programs across India, Africa, and South America. At Novartis, he oversaw the development and approval of more than 35 novel medicines — in one of the most heavily regulated industries on the planet. He’s a member of the US National Academy of Medicine and a trustee at both the University of Chicago and Harvard Medical School.
Why This Matters
This appointment didn’t come out of nowhere. Anthropic already has partnerships with Eli Lilly, Novo Nordisk, and Genmab to accelerate drug development with AI. Narasimhan brings exactly the kind of experience Anthropic needs to be taken seriously in regulated industries.
Daniela Amodei put it simply: ‘Getting powerful new technology to people safely and at scale is what we think about every day.’ Narasimhan has been doing exactly that in pharma for decades.
Trust Now Holds Board Majority
Here’s a detail that’s easy to miss: with Narasimhan’s appointment, directors appointed by the Long-Term Benefit Trust now hold a majority on the board. The Trust is Anthropic’s independent body tasked with ensuring the company doesn’t just succeed financially but stays true to its mission — developing AI for humanity’s long-term benefit. Trust members hold no financial stake in Anthropic.
The board now includes Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, Chris Liddell, and Narasimhan.
My Take
This appointment shows where Anthropic is heading: healthcare and regulated industries are becoming a core business focus. And having a pharma CEO on the board signals seriousness — not just to partners, but to regulators. The fact that the Trust now holds a board majority is a strong governance signal in an industry that’s increasingly facing questions about accountability.
Sources: